NovoCure Limited Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2026-07-01: Study NCT06552000; Company role Collaborator; Phase Not applicable; Status Not yet recruiting.
- 2025-10-30: Study NCT04129515; Company role Collaborator; Phase Phase 1, Phase 2; Status Withdrawn.
- 2025-08-18: Study NCT06906900; Company role Collaborator; Phase Phase 1; Status Recruiting.
- 2024-12-19: Study NCT06136611; Company role Collaborator; Phase Not applicable; Status Recruiting.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2026-07-01 | NCT06552000 Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer | Collaborator Lead: University of Texas Southwestern Medical Center | Not applicable | Not yet recruiting | NSCLC; Non Small Cell Lung Cancer | 18 | 2030-12-01 |
| 2025-10-30 | NCT04129515 NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis | Collaborator Lead: Brown University | Phase 1, Phase 2 | Withdrawn | Metastatic Melanoma; Melanoma Brain Metastasis | 0 | 2026-01 |
| 2025-08-18 | NCT06906900 A Phase I Study of the NovoTTF-200M and Novo TTF-200A Systems for the Treatment of Refractory Spinal Metastasis | Collaborator Lead: M.D. Anderson Cancer Center | Phase 1 | Recruiting | Spinal Metastasis | 30 | 2029-02-17 |
| 2024-12-19 | NCT06136611 Preoperative Preradiotherapy TTFields | Collaborator Lead: The Christie NHS Foundation Trust | Not applicable | Recruiting | Glioblastoma | 42 | 2026-12-30 |
| 2024-08-27 | NCT06222138 Study of Biologic Tumor and Plasma Biomarkers of Response to TTFields in Patients Treated for Newly Diagnosed Glioblastoma | Collaborator Lead: Institut Claudius Regaud | Not applicable | Recruiting | Glioblastoma | 80 | 2029-11 |
| 2024-01-11 | NCT06924099 TTFields General Routine Clinical Care in ndGBM Patients: a French Prospective Non-Interventional Study (TIGER France) | Lead sponsor | Observational | Recruiting | Glioblastoma | 430 | 2029-01-31 |
| 2023-09-21 | NCT05679674 Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer | Collaborator Lead: Baptist Health South Florida | Not applicable | Recruiting | Pancreas Cancer; Locally Advanced; Locally Advanced Pancreatic Adenocarcinoma | 48 | 2027-06 |
| 2023-08-21 | NCT06390059 EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma | Lead sponsor | Phase 2 | Completed | Metastatic Pancreatic Ductal Adenocarcinoma | 84 | 2025-11-18 |
| 2023-08-04 | NCT05764954 A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma | Collaborator Lead: Memorial Sloan Kettering Cancer Center | Phase 1 | Active not recruiting | Adenocarcinoma of Lung | 12 | 2027-08 |
| 2023-08-01 | NCT05538806 TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study | Lead sponsor | Observational | Recruiting | Pleural Mesothelioma | 198 | 2028-06 |
| 2023-01-15 | NCT05086497 WBSI Guided Personalized Delivery of TTFields | Collaborator Lead: Abramson Cancer Center at Penn Medicine | Not applicable | Recruiting | GBM; Glioma Glioblastoma Multiforme; Tumor, Brain | 155 | 2027-06-30 |
| 2022-10-13 | NCT05341349 Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases | Collaborator Lead: Emory University | Phase 1 | Terminated | Clinical Stage IV Cutaneous Melanoma AJCC v8; Melanoma of Unknown Primary; Metastatic Malignant Neoplasm in the Brain; Metastatic Melanoma; Metastatic Mucosal Melanoma; Metastatic Ocular Melanoma; Pathologic Stage IV Cutaneous Melanoma AJCC v8 | 1 | 2024-05-31 |
| 2022-04-01 | NCT04605913 Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC | Collaborator Lead: Mayo Clinic | Phase 1, Phase 2 | Recruiting | Pancreas Cancer; Metastatic Pancreatic Cancer; Pancreatic Adenocarcinoma; Metastatic Adenocarcinoma | 40 | 2028-10-01 |
| 2022-02-28 | NCT05004025 Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma | Collaborator Lead: HonorHealth Research Institute | Phase 1 | Completed | Uveal Melanoma | 10 | 2025-07-23 |
| 2021-12-30 | NCT04717739 TIGER PRO-Active - Daily Activity, Sleep and Neurocognitive Functioning Study | Lead sponsor | Observational | Unknown | Glioblastoma | 500 | 2025-02-01 |
| 2021-05-21 | NCT04474353 Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma | Collaborator Lead: Stanford University | Phase 1 | Completed | Glioblastoma; Newly Diagnosed Glioblastoma | 12 | 2025-09-02 |
| 2021-03 | NCT04804410 Dielectric Properties of Matched Tissue Samples From Thoracic Malignancies and Corresponding Normal Tissues | Collaborator Lead: University of Maryland, Baltimore | Not applicable | Unknown | Lung Cancer; Esophageal Cancer; Mesothelioma; Lung | 30 | 2021-12 |
| 2020-12-08 | NCT04471844 Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM | Lead sponsor | Not applicable | Completed | Glioblastoma Multiforme | 981 | 2026-02-19 |
| 2020-09 | NCT03980249 Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells | Collaborator Lead: West Virginia University | Early Phase 1 | Withdrawn | Glioblastoma; Glioblastoma Multiforme | 0 | 2022-06 |
| 2020-08-31 | NCT03530605 Use of Optune TTF With Radiation as an Alternative for Elderly Patients With Primary CNS Lymphoma | Collaborator Lead: Saint Luke's Health System | Not applicable | Withdrawn | Central Nervous System Neoplasms, Primary | 0 | 2020-08-31 |
| 2020-05-21 | NCT03450850 Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma | Collaborator Lead: Daniela A. Bota | Not applicable | Completed Results posted | Astrocytoma, Grade III | 1 | 2025-08-07 |
| 2019-12-30 | NCT04221503 Niraparib/TTFields in GBM | Collaborator Lead: Abramson Cancer Center at Penn Medicine | Phase 2 | Active not recruiting | Glioblastoma; Recurrent Glioblastoma; GBM | 30 | 2026-01 |
| 2019-12-19 | NCT04281576 Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma | Lead sponsor | Not applicable | Completed | Gastric Cancer; GastroEsophageal Cancer | 28 | 2024-06-07 |
| 2019-12-02 | NCT03705351 Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM | Collaborator Lead: Providence Health & Services | Phase 1 | Terminated Results posted | Glioblastoma; Cancer of Brain; Glioblastoma Multiforme; Brain Tumor | 7 | 2022-02-24 |
| 2019-10-14 | NCT03903640 Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis | Collaborator Lead: Washington University School of Medicine | Phase 2 | Terminated Results posted | Melanoma With Brain Metastasis | 2 | 2021-11-03 |
| 2019-08-09 | NCT03488472 Radiosurgery Plus NovoTTF-200A for Metastatic Small Cell Lung Cancer to the Brain | Collaborator Lead: Drexell Hunter Boggs | Not applicable | Terminated Results posted | Brain Metastases; Small Cell Lung Cancer | 1 | 2022-02-15 |
| 2019-07-24 | NCT03970252 Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer | Collaborator Lead: Jonsson Comprehensive Cancer Center | Early Phase 1 | Completed | Borderline Resectable Pancreatic Adenocarcinoma; Resectable Pancreatic Ductal Adenocarcinoma | 28 | 2024-05-25 |
| 2019-06-11 | NCT03995667 Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung Cancer | Collaborator Lead: OHSU Knight Cancer Institute | Phase 2 | Terminated Results posted | Extensive Stage Lung Small Cell Carcinoma; Limited Stage Lung Small Cell Carcinoma; Stage I Lung Cancer AJCC v8; Stage IA1 Lung Cancer AJCC v8; Stage IA2 Lung Cancer AJCC v8; Stage IA3 Lung Cancer AJCC v8; Stage IB Lung Cancer AJCC v8; Stage II Lung Cancer AJCC v8; Stage IIA Lung Cancer AJCC v8; Stage IIB Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8 | 3 | 2022-08-04 |
| 2019-05-20 | NCT03906448 FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma | Collaborator Lead: University of Florida | Phase 2 | Terminated Results posted | Astrocytoma, Grade II; Astrocytoma, Grade III | 1 | 2020-06-08 |
| 2019-03-22 | NCT03940196 Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3) | Lead sponsor | Phase 3 | Completed | Ovarian Cancer | 540 | 2023-05-18 |
| 2019-02-15 | NCT03606590 Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA) | Lead sponsor | Phase 2 | Completed | Hepatocellular Carcinoma | 25 | 2021-01-14 |
| 2018-12-05 | NCT03430791 Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma | Collaborator Lead: Baptist Health South Florida | Phase 2 | Terminated Results posted | Recurrent Glioblastoma | 5 | 2021-01-27 |
| 2018-09-05 | NCT03607682 Tumor-Treating Fields Therapy in Preventing Brain Tumors in Participants With Extensive-Stage Small Cell Lung Cancer | Collaborator Lead: Vanderbilt-Ingram Cancer Center | Not applicable | Terminated Results posted | Extensive Stage Small Cell Lung Carcinoma | 2 | 2020-07-13 |
| 2018-08-08 | NCT03501134 Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating Fields | Collaborator Lead: Duke University | Observational | Completed | Malignant Glioma | 20 | 2021-06-03 |
| 2018-05-10 | NCT03377491 Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3) | Lead sponsor | Phase 3 | Completed Results posted | Pancreas Adenocarcinoma | 571 | 2024-10-16 |
| 2018-05-04 | NCT03477110 Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma | Collaborator Lead: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Early Phase 1 | Completed | Glioblastoma | 30 | 2024-01-26 |
| 2018-03-01 | NCT03223103 Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma | Collaborator Lead: Adilia Hormigo | Phase 1 | Active not recruiting | Glioblastoma | 13 | 2029-05-12 |
| 2018-02-23 | NCT03405792 Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP) | Collaborator Lead: University of Florida | Phase 2 | Active not recruiting Results posted | Glioblastoma; Glioblastoma, WHO Grade IV | 40 | 2027-12 |
| 2017-12-15 | NCT03353896 NovoTTF-200A Device in Treating Patients With Newly Diagnosed High Risk Oligodendroglioma | Collaborator Lead: University of Southern California | Not applicable | Withdrawn | Anaplastic Oligodendroglioma; Oligoastrocytoma; Oligodendroglioma | 0 | 2020-12-08 |
| 2017-08-31 | NCT03258021 TTFields In GErmany in Routine Clinical Care | Lead sponsor | Observational | Unknown | Glioblastoma | 710 | 2021-07 |
| 2017-07-26 | NCT03232424 NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma | Collaborator Lead: Hackensack Meridian Health | Phase 1 | Completed | Glioblastoma, Adult | 12 | 2022-12-07 |
| 2017-05-09 | NCT02743078 Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma | Collaborator Lead: RTOG Foundation, Inc. | Phase 2 | Terminated Results posted | Glioblastoma; Glioma; Gliosarcoma | 3 | 2019-10-15 |
| 2017-04-27 | NCT03780569 TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBM | Lead sponsor | Not applicable | Unknown | Glioblastoma Multiforme | 10 | 2019-01 |
| 2017-04-17 | NCT02507232 Study of NovoTTF-200A Alone and With Temozolomide in Patients With Low-Grade Gliomas | Collaborator Lead: Santosh Kesari | Early Phase 1 | Terminated | Glioma | 2 | 2020-07-27 |
| 2017-04-06 | NCT03128047 HUMC 1612: Optune NovoTTF-200A System | Collaborator Lead: Hackensack Meridian Health | Phase 1 | Completed Results posted | High Grade Glioma; Ependymoma | 7 | 2025-04-05 |
| 2017-04-04 | NCT03033992 Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG | Collaborator Lead: Children's Oncology Group | Not applicable | Active not recruiting | Malignant Glioma; Ependymoma; Diffuse Intrinsic Pontine Glioma | 80 | 2032-07-22 |
| 2016-12-19 | NCT02663271 TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma | Collaborator Lead: University of Florida | Phase 2 | Terminated Results posted | Glioblastoma Multiforme; Glioblastoma; Malignant Glioma; GBM | 10 | 2021-06-11 |
| 2016-10-01 | NCT02893137 Enhancing Optune Therapy With Targeted Craniectomy | Collaborator Lead: Aarhus University Hospital | Phase 1 | Completed | Glioblastoma | 15 | 2019-05-31 |
| 2016-08-01 | NCT02847559 Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma | Collaborator Lead: Northwestern University | Phase 2 | Completed | Anaplastic (Malignant) Meningioma; Atypical Meningioma; Grade II Meningioma; Grade III Meningioma; Recurrent Meningioma; Supratentorial Meningioma | 20 | 2026-05-01 |
| 2016-01 | NCT02348255 NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse | Collaborator Lead: University of California, Davis | Phase 2 | Withdrawn | Adult Brain Glioblastoma; Recurrent Adult Brain Neoplasm | 0 | 2017-01 |
| 2015-02 | NCT02397928 Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR) | Lead sponsor | Phase 2 | Completed | Malignant Pleural Mesothelioma | 82 | 2018-04 |
| 2015-01 | NCT02343549 A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM) | Collaborator Lead: Wake Forest University Health Sciences | Phase 2 | Terminated Results posted | Cancer of Brain and Nervous System | 13 | 2020-07-11 |
| 2014-09 | NCT02244502 Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE) | Lead sponsor | Phase 1, Phase 2 | Unknown | Ovarian Carcinoma | 31 | 2016-12 |
| 2014-07 | NCT02367482 Tryptophan Metabolism in Human Brain Tumors-Novocure | Collaborator Lead: Wayne State University | Observational | Completed | Glioblastoma | 20 | 2023-12-31 |
| 2014-05 | NCT01925573 Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344) | Collaborator Lead: University of Maryland, Baltimore | Not applicable | Terminated Results posted | RECURRENT GLIOBLASTOMA; Brain Tumor | 7 | 2019-08 |
| 2013-11 | NCT01971281 Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA) | Lead sponsor | Phase 1, Phase 2 | Unknown | Pancreatic Adenocarcinoma | 40 | 2017-12 |
| 2013-10-10 | NCT01954576 NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme | Collaborator Lead: University of Florida | Not applicable | Terminated | Glioblastoma; Brain Neoplasms | 21 | 2021-05-14 |
| 2013-09-18 | NCT01894061 NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma | Collaborator Lead: Case Comprehensive Cancer Center | Phase 2 | Completed Results posted | Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor | 25 | 2019-07-01 |
| 2013-06 | NCT01892397 Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma | Collaborator Lead: Memorial Sloan Kettering Cancer Center | Not applicable | Active not recruiting | Brain Cancer | 6 | 2027-06 |
| 2013-01 | NCT01755624 Effect of TTFields (150kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-5 Brain Metastases Following Optimal Standard Local Treatment (COMET) | Lead sponsor | Phase 2 | Unknown | 1-5 Brain Metastases From Non-Small Cell Lung Cancer | 18 | 2017-07 |
| 2012-12 | NCT01756729 Post-approval Study of NovoTTF-100A in Recurrent GBM Patients | Lead sponsor | Phase 4 | Terminated | Recurrent Glioblastoma Multiforme | 13 | 2018-01 |
| 2009-06 | NCT00916409 Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) | Lead sponsor | Phase 3 | Completed | Glioblastoma Multiforme | 700 | 2017-03 |
| 2008-05 | NCT00749346 NovoTTF-100L in Combination With Pemetrexed (Alimta®) for Advanced Non-small Cell Lung Cancer | Lead sponsor | Phase 1, Phase 2 | Completed | Non-small Cell Lung Cancer; NSCLC | 42 | 2011-07 |
| 2006-09 | NCT00379470 Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM) | Lead sponsor | Phase 3 | Completed | Recurrent Glioblastoma Multiforme | 236 | 2011-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEMAITRE VASCULAR INC (LMAT) | United States | $1.848B | 33.37 |
| Inspire Medical Systems, Inc. (INSP) | United States | $1.990B | 9.55 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| UFP TECHNOLOGIES INC (UFPT) | United States | $2.308B | 28.37 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |